Hempel to divest J.W. Ostendorf and Renaulac as next step on strategic journey

07 May 2024

The prospective new owner, Fidelium Partners, would take over the production site in Germany and stores in France, together with around 500 employees and a portfolio of customers.

Key messages

  • Hempel A/S announces its intention to divest J.W. Ostendorf and Renaulac.
  • The sale would include a production site in Germany, stores in France, around 500 employees and a portfolio of customers.
  • This sale would see Hempel take the next step on its strategic journey and focus its portfolio on the branded decorative business.
  • The sale is expected to be completed in Q3 2024, pending relevant approvals.

World-leading supplier of paint and coatings, Hempel A/S, has signed an agreement to divest its J.W. Ostendorf and Renaulac business in France and Germany to Fidelium Partners, subject to relevant approvals.

The sale of Hempel’s predominantly private label business marks the next step on its ambitious growth strategy and brings strategic focus on growing the branded business in its Decorative customer segment.


From beverages to coatings: PPCJ speaks to Hempel’s new EVP & Head of Decorative

Hempel acquired the predominantly private label business, J.W. Ostendorf and Renaulac, in 2018. Since then, Hempel has built a portfolio of decorative brands through further acquisitions, which now make up the majority of Hempel’s Decorative segment and comprise Farrow & Ball, Crown Paints, Hempel and Wattyl.

“In pursuit of achieving Hempel’s ambitious Double Impact strategy, we have made the strategic decision to focus on our full-service Deco brands within our Decorative segment,” says Ana Henriques, Executive Vice President and Head of Decorative at Hempel A/S. “The consequence of that focus is the sale of J.W. Ostendorf and Renaulac. In Fidelium Partners, we have found a committed new prospective owner with a long-term interest in growing the business. We believe that we have found a good new home for our around 500 colleagues from J.W. Ostendorf and Renaulac.”

The sale is expected to be completed in Q3 2024, pending relevant approvals. Transactional details will remain confidential, according to the terms of the purchase agreement.

< Previous article

Axalta releases Q1 2024 results

Next article >

Masterpress commits to set science-based targets for greenhouse gas emissions reduction